Info

Myriad Genetics, Inc. is a healthcare company focused on the development and marketing of molecular diagnostic and therapeutic products. The Company’s molecular diagnostic business focuses on the analysis of genes and their alterations to assess an individual’s risk for developing disease later in life (predictive medicine) and to assess a patient’s risk of disease progression, disease recurrence, drug toxicity, and drug response (personalized medicine). As of June 30, 2008, the Company had launched five commercial molecular diagnostic products, including both predictive medicine and personalized medicine products. Its commercial molecular diagnostic products include BRACAnalysis, COLARIS, COLARIS AP, MELARIS and THERAGUIDE 5-FU. It markets these products through its own person sales force in the United States and it has entered into marketing collaborations with other organizations in selected foreign countries. On April 10, 2008, the Company acquired NaturNorth Technologies, LLC.(Source: 10-K)